The global actinic keratosis treatment market is set for substantial growth, with sales expected to rise from USD 6,128.2 million in 2024 to USD 12,282.4 million by 2034. The market is projected to grow at a CAGR of 7.2% during the forecast period from 2024 to 2034.
This surge in demand is largely attributed to the growing prevalence of skin cancer and the increasing adoption of advanced treatment technologies. As awareness around the risks of actinic keratosis and its potential to progress into skin cancer continues to spread, healthcare systems and regulatory bodies are focusing more on effective treatment solutions.
Key Growth Drivers
The rise in skin cancer incidence, driven by factors such as sun exposure and an aging population, is pushing the demand for actinic keratosis treatments. Moreover, ongoing advancements in treatment technologies are expected to significantly contribute to the market’s growth, offering more efficient and non-invasive solutions for patients.
For more detailed insights into the market dynamics and trends, Future Market Insights provides a comprehensive report on the actinic keratosis treatment market.
Competitive Landscape
By developing effective and innovative treatment options, key actinic keratosis treatment market players are ready to gain a major industry share in the current period. Several key players are authenticating their treatment by getting government approvals to gain consumer trust. Moreover, pharmaceutical industry players are playing a major role in the industry by developing and supplying essential drugs and medicines.
Strategies for stakeholders to unlock industry potential
- Developing innovative products with efficiency and safety
- Creating a competitive pricing strategy
- Implementing marketing and promotional activities
- Expanding geographically for better revenue growth
Recent Development
- In 2024 , Torqur AG, a leading clinical-stage pharmaceutical company, announced that the first patient has been dosed in the Phase 2 clinical trial of Bimiralisib for the treatment of Actinic Keratosis. Actinic Keratosis is a common skin condition that affects millions of people worldwide and is typically caused by overexposure to sunlight. Bimiralisib is a novel, highly selective, and potent PI3Kδ inhibitor that has shown promising results in pre-clinical studies. The Phase 2 clinical trial aims to evaluate the safety and efficacy of Bimiralisib in patients with Actinic Keratosis and is expected to enroll approximately 200 patients across multiple centers in Europe and the United States. This milestone marks a significant step forward in the development of Bimiralisib and brings hope to those suffering from Actinic Keratosis.
- In 2024, Biofrontera Inc, a biopharmaceutical company specializing in the treatment of skin disorders, filed a supplemental New Drug Application (sNDA) for an increased dosage of Aminolevulinic Acid Hydrochloride (ALA HCl) for the treatment of Actinic Keratosis (AK). AK is a common skin condition caused by long-term sun exposure that can lead to the development of skin cancer if left untreated. ALA HCl is a photosensitizing agent used in photodynamic therapy to destroy precancerous and cancerous skin cells selectively. The sNDA requests the approval of an increased dosage of ALA HCl from 20% to 30% for the treatment of AK. This filing marks an important milestone for Biofrontera as it seeks to expand the treatment options for patients with AK.
- In 2022, Jupiter Wellness completed recruitment for the JW-200 clinical trial. This uses a combination of aspartame and cannabidiol to provide quick relief and effectiveness for AK lesions and as a treatment for skin cancer. This treatment is a dual mechanism of action cox-2 inhibitor, and the completion of this trial is a significant step for the company in bringing this potentially groundbreaking treatment to market.
Key Companies Profiled:
3M Health Care Ltd.;
Alma Lasers Ltd.;
Biofrontera AG;
Bausch Health Companies Inc.;
CryoConcepts LP;
Cutera Inc.;
DUSA Pharmaceuticals, Inc.;
Galderma S.A.;
Key Segments:
By Treatment Type:
Depending on the treatment type, the industry is categorized into a topical treatment and procedural modality. The topical treatment category is further divided into 5-fluorouracil cream, diclofenac gel, imiquimod cream, and ingenol mebutate gel. Also, procedural modality is divided into chemical peels, cryotherapy, photodynamic therapy, and others.
By Disease Type:
The actinic keratosis treatment is effective in clinical and subclinical disease types.
By End User:
The key end-user industries are hospitals, private dermatology clinics, laser therapy centers, cancer treatment centers, spas and rejuvenation centers, and home care.
By Region:
Regional analysis is conducted of the industry in North America, Latin America, Europe, South Asia, East Asia, and Oceania, as well as the Middle East and Africa.
Author
Sabyasachi Ghosh (Associate Vice President at Future Industry Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Industry Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Industry Insights (FMI)
Future Industry Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the Industry. FMI is the leading global provider of Industry intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals Industry. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Industry Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futureIndustryinsights.com
Website: https://www.futureIndustryinsights.com
LinkedIn| Twitter| Blogs | YouTube
